newsfilter
← Latest News
GlobeNewswire·

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 millionExpanded CARVYKTI® availability to 348 global sites and 19 global markets with